Project governance

Project governance

Governing bodies

The Executive Steering Committee (ESC) is common to Ebola+ projects in which Janssen is participating and makes high-level decisions with regards to these Ebola+ projects. The ESC will be chaired by Crucell Holland B.V, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen).


The Clinical Steering Committee (CSC) is common to EBOVAC1 and EBOVAC2 projects and makes high-level decisions and approvals regarding implementation strategies and dispute resolution for issues arising from the Management Committee (MC). Issues that cannot be resolved by the CSC will be escalated to the ESC. The CSC will be chaired by Janssen.

The EBOVAC2 Management Committee (MC) is in charge of the overall steering (contractual, clinical and scientific) of the project in line with the decisions made by the Clinical Steering Committee, the Executive Steering Committee and the advice provided by the External Advisory Groups. The EBOVAC2 MC will be chaired by Inserm.

Independent advisory boards

Scientific Advisory Boards

The Scientific Advisory Board (SAB) is a consultative body composed of independent inter-disciplinary scientific experts whose role is to provide scientific advice to all projects funded under the Ebola+ programme to ensure maximum impact in scientific, technological and health terms for all concerned parties. The SAB will, where and when relevant, review project deliverables, advise on scientific and technologic choices and for this purpose attend key project events. The SAB will be set up and managed by Inserm with the support of Inserm Transfert (EBOVAC2).

Ethics Board

The Ethics board will have a consultative role in the project and be asked, where and when relevant, to attend project meetings. The final list of sites, the final study protocol, approbation of Ethics Board, and clinical trial registration number will always be provided to IMI2JU. The Ethics Boards will be set up managed by LSHTM (EBOVAC1).

NEWS

  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 115861.
This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA

Cookies settings

×

Functional Cookies

This site uses cookies to ensure its proper functioning and cannot be deactivated from our systems. We do not use them for advertising purposes. If these cookies are blocked, certain parts of the site will not be able to function.

Measure of audience

This site uses audience measurement and analysis cookies, such as Google Analytics, in order to evaluate and improve our website.

Interactive Content

This site uses third-party components, such as ReCAPTCHA, Google Maps, which may deposit cookies on your machine. If you decide to block a component, the content will not be displayed

Other cookies

Our wepage uses cookies to manage user sessions